Exploring the impact of GLP-1 analogues and DPP-4 inhibitors on cognitive decline in elderly patients with type 2 diabetes: a competing risks analysis from a real-world cohort
- 1Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of BioPharmacovigilance & Clinical Research, Intmedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano
- 2Medical Statistics Unit, Department of Biomedical and Clinical Sciences L. Sacco, “Luigi Sacco” University Hospital, Università degli Studi di Milano
- 3Pharmaceutical Department, ASL BT
Abstract
Background: Older adults with type 2 diabetes (T2DM) face an increased risk of cognitive decline. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown neuroprotective effects, comparative evidence versus dipeptidyl peptidase-4 inhibitors (DPP-4i) in real-world older populations is limited.
Methods: We conducted a retrospective cohort study using health administrative data, including individuals aged ≥65 initiating GLP-1RAs or DPP-4i therapy between 2010 and 2018. Patients with prior cognitive disorders were excluded. The primary outcome was a composite of incident cognitive disorders or death. Analyses were adjusted for clinical and demographic characteristics. Marginal structural models and competing risks methods were used to estimate treatment effects. Both an ‘As treated’ (AT) and an ‘Intention to Treat’ (ITT) designs were employed.
Results: A total of 2,579 individuals were included (GLP-1RAs: 393; DPP-4i: 2,186), with a median follow-up of 44 months in the AT analysis. GLP-1RAs users had a lower risk of the composite outcome, especially in the early follow-up (HR at 2 years: 0.5 [95% CI: 0.26–0.93]). Competing-risk analysis showed a lower early risk of death without prior cognitive disorders among GLP-1RA initiators. The point estimate of sub-distribution HR was 0.4 also for cognitive disorders, yet not statistically significant because of the small number of events.
Conclusion: GLP-1RAs use was associated with a lower early risk of the composite outcome of cognitive disorders or death compared with DPP-4i in older adults with T2DM. The observed association with cognitive disorders alone was directionally consistent with a potentially lower risk, but the very small number of events precludes firm conclusions regarding a protective effect on cognitive outcomes. Longer follow-up and cognitive-specific evaluations are needed to confirm these associations.
Related
- N6-Substituted adenosine analogues, a novel class of JAK2 inhibitors, potently block STAT3 signaling in human cancer cells
- Synthetic Flavonoid Analogues as CatB/CatL Inhibitors with Potential Anti-SARS-CoV-2 Activity
- The Association between Marital Status and Suicide Risk Among Patients with Breast Cancer A Population-Based sIPTW Competing Risk Analysis
- Changing cause-of-death composition among patients undergoing gastrectomy for stage I–III gastric adenocarcinoma: a SEER landmark competing-risk analysis of mortality from diagnosis
- Exploring Epigenetic Aging and Cognitive Change in Middle Adulthood
BibTeX
@article{battini2026exploring,
title = {{Exploring the impact of GLP-1 analogues and DPP-4 inhibitors on cognitive decline in elderly patients with type 2 diabetes: a competing risks analysis from a real-world cohort}},
author = {Vera Battini and Giacomo Biganzoli and Federica Di Pierro and Annamaria Pia Terlizzi and Francesca Vittoria Rizzi and Domenica Ancona and Patrizia Boracchi and Carla Carnovale},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1822158},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1822158/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Exploring the impact of GLP-1 analogues and DPP-4 inhibitors on cognitive decline in elderly patients with type 2 diabetes: a competing risks analysis from a real-world cohort
AU - Vera Battini
AU - Giacomo Biganzoli
AU - Federica Di Pierro
AU - Annamaria Pia Terlizzi
AU - Francesca Vittoria Rizzi
AU - Domenica Ancona
AU - Patrizia Boracchi
AU - Carla Carnovale
PY - 2026
DA - 2026/10/15
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1822158
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1822158/full
AB - Background: Older adults with type 2 diabetes (T2DM) face an increased risk of cognitive decline. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown neuroprotective effects, comparative evidence versus dipeptidyl peptidase-4 inhibitors (DPP-4i) in real-world older populations is limited. Methods: We conducted a retrospective cohort study using health administrative data, including individuals aged ≥65 initiating GLP-1RAs or DPP-4i therapy between 2010 and 2018. Patients with prior cognitive disorders were excluded. The primary outcome was a composite of incident cognitive disorders or death. Analyses were adjusted for clinical and demographic characteristics. Marginal structural models and competing risks methods were used to estimate treatment effects. Both an ‘As treated’ (AT) and an ‘Intention to Treat’ (ITT) designs were employed. Results: A total of 2,579 individuals were included (GLP-1RAs: 393; DPP-4i: 2,186), with a median follow-up of 44 months in the AT analysis. GLP-1RAs users had a lower risk of the composite outcome, especially in the early follow-up (HR at 2 years: 0.5 [95% CI: 0.26–0.93]). Competing-risk analysis showed a lower early risk of death without prior cognitive disorders among GLP-1RA initiators. The point estimate of sub-distribution HR was 0.4 also for cognitive disorders, yet not statistically significant because of the small number of events. Conclusion: GLP-1RAs use was associated with a lower early risk of the composite outcome of cognitive disorders or death compared with DPP-4i in older adults with T2DM. The observed association with cognitive disorders alone was directionally consistent with a potentially lower risk, but the very small number of events precludes firm conclusions regarding a protective effect on cognitive outcomes. Longer follow-up and cognitive-specific evaluations are needed to confirm these associations.
SN - 1663-9812
ER -